- Home
- NMG vs ACRS Comparison
NMG vs ACRS Comparison
Compare NMG & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | ACRS |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.7M | 311.0M |
| IPO Year | 2015 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NMG | ACRS |
|---|---|---|
| Price | $2.34 | $4.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | $4.75 | ★ $9.75 |
| AVG Volume (30 Days) | 683.3K | ★ 2.5M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.01 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,683,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.30 | $1.05 |
| 52 Week High | $6.06 | $4.89 |
Technical Indicators
Market Signals| Indicator | NMG | ACRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.51 | 66.39 |
| Support Level | $1.97 | $2.67 |
| Resistance Level | $2.44 | $4.89 |
| Average True Range (ATR) | 0.15 | 0.26 |
| MACD | 0.03 | 0.05 |
| Stochastic Oscillator | 78.22 | 98.04 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The company currently operates in two segments: the Matawinie Mine Project and the Battery Material Plant project.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.